Roche reports positive studies of MabThera given by subcutaneous injectionPipelineReview.com (press release)BASEL, Switzerland I December 8, 2012 I Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two studies which showed that a fixed do…
 Healio |
Combination of ibrutinib and rituximab produced high response rates in high …
Healio ATLANTA — The combination of ibrutinib and rituximab produced favorable overall response rates among high-risk patients with chronic lymphocytic leukemia, according to study results presented at the 2012 American Society of Hematology Meeting and … |
ROCHE HOLDING LTD. : Roche reports positive studies of MabThera given by …4-tradersRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two studies which showed that a fixed dose of MabThera (rituximab) can be administered subcutaneously (…
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 …The Herald | HeraldOnline.comA second study in 40 patients with HR CLL treated with the combination of ibrutinib and rituximab therapy reported an ORR of 83 percent, with 38 …
Clinical Oncology NewsHematology & Stem Cell Transplantation ProgramClinical Oncology NewsThe majority of clinical responses with SAR3419 were seen in patients with follicular lymphoma, including those who were rituximab refractory. SAR3419 (huB4-D…
B-cell alterations in ME/CFS 'may suggest subtle tendency to autoimmunity'ProHealthHowever, treatment with anti-B-cell therapy using Rituximab has recently shown benefit to CFS patients. We therefore postulated that patients with CFS had a subt…
Rethinking therapy decisions in autoimmune encephalopathyNews-Medical.netFirst-line immunotherapies (corticosteroids, intravenous immunoglobulins, and plasma exchange) were given to 29 patients, while five required regular immunosuppressive treatment w…
Mundipharma to present bendamustine data at ASH meetingPharmaceutical Business ReviewTwo oral and three poster presentations will present summary on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standard firs…
MedscapeWhat's Hot at ASH This Year?MedscapeToxicity is a problem in the treatment of CLL, where the standard therapy is a combination of fludarabine, cyclophosphamide, and rituximab. This improves outcomes, but is reasonably toxic for older patien…
Kirkman appreciates MLB's Stand Up To CancerTexasRangers.comKirkman, while playing for Round Rock, began a series of treatments with a chimeric monoclonal antibody called Rituximab, which destroys the b cells that cause the cancer. He was scheduled…